In a recent paper in the Journal of Nuclear Medicine, Tagworks, in collaboration with Austrialian biotech company Avipep, describes an alternative radioimmunotherapy strategy based on separate administration of the tumor-homing agent and a fast clearing radioactive probe. This way, the unwanted high renal retention of low-molecular weight radiometal tumor-homing agents can …

Tagworks Pharmaceuticals has received two valorization grants, €180,000 total, from NanoNextNL, the Dutch research and innovation program on nanotechnology. The grants will be used to take two of the company's core programs to the next level. One grant concerns Tagworks' antibody drug conjugate (ADC) technology and will be applied to further …

For their proposal "Click chemistry-triggered activation of Antibody-Drug Conjugates", Tagworks Pharmaceuticals and the research group of professor Paul Yazaki at the Department of Immunology, City of Hope Beckman Research Institute in Duarte, CA, were awarded a US$465,000 Breakthrough Award through the Breast Cancer Research Program (BCRP) of the US Department …

The latest edition of Medicines, a Dutch journal on drug development, features Tagworks Pharmaceuticals in the start-up sections. The article by Rik Nijland appeared in Medicines 1, February 2015 (in Dutch) 24_25_med1_startup

Developing an antibody tag with improved pharmacokinetics and stability allowed Tagworks to achieve increased tumor uptake of a radiolabeled pretargeting probe. Even though this adapted tag exhibited a slight loss in reactivity, its use in a antibody (CC49-TCO) conjugate demonstrated a longer clearance half-life, improved tumor accumulation and increased in …

Approaches that use in vivo chemistry to enable non-invasive molecular imaging and therapy are much sought after. Taking the recent achievements in pretargeted radioimmuno-imaging and -therapy in mice as a starting point, the Tagworks team discuss how the application scope of this approach can eventually be extended towards humans. Read …

Marc Robillard, CEO of Tagworks Pharmaceuticals has been invited to speak during the Gordon Research Conference on Organic Reactions and Processes, held from 13-18 July 2014 at Bryant University, Smithfield, RI. In his lecture entitled "In vivo Chemistry for Cancer Imaging and Therapy" Marc Robillard will present the company's R&D …

Together with prof. Tom Quinn of the University of Missouri-Columbia, Tagworks succeeded in securing an Exploratory/Development grant from the US National Institutes of Health (NIH) Innovative Molecular Analysis Technologies (IMAT) program for the project "In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy". The proposal was ranked in the top …

By modifying the fastest and highly selective click reaction, the inverse-electron-demand-Diels-Alder reaction, Tagworks has achieved selective bioorthogonal release. This holds promise for the chemically triggered release, and thus activation, of drugs from tumor-bound Antibody-Drug Conjugates (ADCs), which would greatly enhance the scope of suitable ADC targets. Published in: Angewandte Chemie …

Tagworks' pretargeting technology can boost tumor/non-tumor ratios compared with conventional radioimmunoimaging and -therapy. Published in Journal Nuclear Medicine 2013, 54, 11, 1989-1995 doi:10.2967/jnumed.113.12.3745